| answer text |
<p>The National Institute for Health and Care Excellence (NICE) is currently developing
guidance on the use of Spinraza (nusinersen) for the treatment of spinal muscular
atrophy, including types 2 and 3.</p><p> </p><p>NHS England and NICE have been in
discussions with the manufacturer of Spinraza, Biogen, to explore whether there are
commercial flexibilities that might enable NICE to recommend the drug as a clinically
and cost effective use of NHS resources. Biogen has now submitted a revised submission
for NICE’s independent Appraisal Committee to consider and a meeting has been arranged
for 6 March 2019 to consider the recommendations. In the absence of final guidance
from NICE, clinicians can apply to NHS England for funding in exceptional cases through
the individual funding request process.</p>
|
 |
